Elsevier

Neuropharmacology

Volume 125, October 2017, Pages 254-262
Neuropharmacology

Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species

https://doi.org/10.1016/j.neuropharm.2017.07.031Get rights and content

Highlights

  • Modafinil improved attention in healthy, non-sleep deprived volunteers.

  • Attention is improved at doses that do not induce hyperarousal, indicating domain specificity.

  • Modafinil doses producing hyperarousal in mice may not reflect therapeutic doses in humans.

Abstract

The wake-promoting drug modafinil is frequently used off-label to improve cognition in psychiatric and academic populations alike. The domain-specific attentional benefits of modafinil have yet to be quantified objectively in healthy human volunteers using tasks validated for comparison across species. Further, given that modafinil is a low-affinity inhibitor for the dopamine and norepinephrine transporters (DAT/NET respectively) it is unclear if any effects are attributable to a non-specific increase in arousal, a feature of many catecholamine reuptake inhibitors (e.g., cocaine, amphetamine). These experiments were designed to test for domain-specific enhancement of attention and cognitive control by modafinil (200 and 400 mg) in healthy volunteers using the 5-choice continuous performance task (5C-CPT) and Wisconsin Card Sort Task (WCST). An additional cross-species assessment of arousal and hyperactivity was performed in this group and in mice (3.2, 10, or 32 mg/kg) using species-specific versions of the behavioral pattern monitor (BPM). Modafinil significantly enhanced attention (d prime) in humans performing the 5C-CPT at doses that did not affect WCST performance or induce hyperactivity in the BPM. In mice, only the highest dose elicited increased activity in the BPM. These results indicate that modafinil produces domain-specific enhancement of attention in humans not driven by hyperarousal, unlike other drugs in this class, and higher equivalent doses were required for hyperarousal in mice. Further, these data support the utility of using the 5C-CPT across species to more precisely determine the mechanism(s) underlying the pro-cognitive effects of modafinil and potentially other pharmacological treatments.

Introduction

Cognitive deficits, particularly in the domains of attention and cognitive control, are key features of multiple psychiatric illnesses, e.g., schizophrenia (SCZ), bipolar disorder (BD), and attention deficit hyperactivity disorder (ADHD). Traditional treatments such as methylphenidate have been considered as therapeutic agents in the treatment of impaired attention and cognitive control. There has been longstanding reticence to use these drugs for individuals with SCZ and BD however, since they can exacerbate many of their symptoms (Chiarello and Cole, 1987). Further, given the mechanism of action of stimulants in potently blocking or reversing the dopamine transporter (DAT), these drugs carry a high potential for abuse (Volkow and Swanson, 2003). The lack of pro-cognitive pharmacotherapies with low abuse potential stands as a critical treatment gap for individuals suffering from these illnesses (Fusar-Poli et al., 2015, Geddes and Miklowitz, 2013, Lindenmayer et al., 2013).

Modafinil, a low potency inhibitor of the DAT and norepinephrine transporter (NET), is a Federal Drug Administration-approved compound that was developed to increase wakefulness in the treatment of narcolepsy (Madras et al., 2006, Volkow et al., 2009). This drug however, is increasingly used off-label to remediate deficient attention and cognitive control in psychiatric patients (Minzenberg and Carter, 2008), as well as a cognition-enhancing aid in academic institutions (Sahakian and Morein-Zamir, 2015). Certainly, there are myriad findings reporting modafinil-induced improved working memory, cognitive control, and sustained attention in healthy sleep-deprived volunteers, psychiatric populations, and rodents (Sahakian and Morein-Zamir, 2015). Improved cognition in non-sleep deprived healthy adults has been rarely observed however (Baranski et al., 2004, Battleday and Brem, 2015, Muller et al., 2004), except at the highest levels of difficulty in working memory, or in higher order planning and decision-making tasks (Battleday and Brem, 2015, Muller et al., 2013, Turner et al., 2003). Modafinil-induced improvements in the attentional domain have yet to be observed in healthy adults, which contrasts with what has been seen with high-potency DAT inhibitors such as amphetamine (Linssen et al., 2014, Smith and Farah, 2011).

In addition to improving attention, high-potency DAT inhibitors such as amphetamine also increase arousal (Bensadoun et al., 2004, Berridge, 2006, Kalivas and Volkow, 2005), an effect linked to its abuse potential (Sahakian and Morein-Zamir, 2015). In both healthy human volunteers and mice, d-amphetamine increases activity in the behavioral pattern monitor (BPM) at clinically relevant doses (Minassian et al., 2016). Similarly, modafinil increases activity in the mouse BPM (Young et al., 2011a) and increases motivation in mice as measured by progressive ratio breakpoint (Young and Geyer, 2010) at similar doses (32 mg/kg). It would therefore be important to separate the potential effect of modafinil on attention from its effects on arousal. In terms of feedback-related decision-making, amphetamine increased safe lever choice preference (preference for low risk, low reward option), while the more selective DAT inhibitor GBR12909 worsened performance, and modafinil had no effect in a mouse consolidation-dependent Gambling Task (van Enkhuizen et al., 2013b). This suggests a separation of the effect of modafinil from other DAT inhibitors in a risk-based decision-making task. The effect of modafinil on various psychiatric-related behaviors, however, remains unclear. The use of cross-species tasks would enable future studies to investigate mechanism-related effects of modafinil in rodents using neuroscience tools not available for testing in humans.

In an attempt to parse these potential domains of effect, we assessed the effects of clinically relevant doses of modafinil in healthy, non-sleep deprived human volunteers in the five-choice continuous performance task (5C-CPT), Wisconsin Card Sort Task (WCST), and the human BPM. These tests are validated for the assessment of attention and cognitive control (Cope et al., 2016, Lustig et al., 2013), and arousal and exploration (Minassian et al., 2011, Perry et al., 2009, van Enkhuizen et al., 2013a), respectively. We also determined the effects of modafinil on the arousal and exploratory behavior of male and female mice at doses that are directly comparable to those used in human testing. Given the separation of effects for more selective DAT inhibitors, we hypothesized that modafinil would improve attention without inducing hyperarousal.

Section snippets

Volunteer recruitment

Procedures were approved by The University of California San Diego (UCSD) School of Medicine's institutional review board. Using online advertisements and flyers posted throughout the community, 61 male and female participants were recruited according to the following inclusion criteria: 1) Ages 18–35; 2) In good general health; 3) No lifetime history of an axis I or axis II disorder; 4) No first-degree relative with a history of psychotic or mood disorder; and 5) No specific contraindications

Demographics and treatment randomization

Demographic information and treatment group sample sizes are reported in Table 2. Although a greater number of female participants participated in this study, the gender difference did not reach statistical significance (Pearson χ2(1,62) = 1.61, p = 0.20). There were more females than males in the modafinil groups; this difference approached statistical significance (Fisher's Exact Test (2,62) = 4.43, p = 0.11). Participants did not differ significantly in terms of age (F(2,61) = 1.32, n.s.) or

Discussion

Here, we report that modafinil improved 5C-CPT performance. Further, enhancement of attention/cognitive control was achieved at doses that did not induce hyperarousal in either healthy volunteers or mice. Therefore, it appears that the pro-cognitive effects of modafinil may be domain-specific, occurring independently from the levels of arousal induced by similar drugs, supporting its use as a pro-cognitive pharmacotherapy with a likely limited abuse potential.

Modafinil significantly improved

Conclusions

In summary, it is clear that modafinil effectively enhances cognitive ability within the domain of attention and cognitive control in healthy adult volunteers. Further, this pro-cognitive effect is domain-specific insofar as it is achieved at doses that did not result in hyperactivity. Although the precise mechanism underlying this effect remains to be determined, the availability of rat and mouse 5C-CPTs (Barnes et al., 2012a, Barnes et al., 2012b, Young et al., 2015, Young et al., 2011b)

Disclosure of biomedical financial interests and potential conflicts of interest

Dr. Geyer has received consulting compensation from Lundbeck, Omeros, Otsuka, and Sunovion, and holds an equity interest in San Diego Instruments. Dr. Young has received funding from Cerca Insights and Lundbeck Ltd, and has received consulting compensation for Amgen, and honoraria from Arena Pharmaceuticals and Sunovion. Drs. Cope, Perry, Minassian, and MacQueen, plus Ms. Kreitner and Milienne-Petiot report no biomedical financial interests or potential conflict of interest.

Acknowledgements

We thank all of the participants who volunteered for these studies, which were made possible by funding from NIMH grants R01MH104344-03, UH2MH109168–01, R01 MH071916, and T32MH018399-30, as well as by the Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center. They have full control of all primary data. The authors thank Dr. Harriet De Wit for her assistance in designing this study, and Mahalah Buell, Elise Winbrock, and Karen Kloezeman for their contributions

References (62)

  • B.S. McKenna et al.

    Bridging the bench to bedside gap: validation of a reverse-translated rodent continuous performance test using functional magnetic resonance imaging

    Psychiatry Res.

    (2013)
  • A. Minassian et al.

    The quantitative assessment of motor activity in mania and schizophrenia

    J. Affect Disord.

    (2010)
  • U. Muller et al.

    Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers

    Neuropharmacology

    (2013)
  • M.P. Paulus et al.

    A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (1991)
  • M.P. Paulus et al.

    Three independent factors characterize spontaneous rat motor activity

    Behav. Brain Res.

    (1993)
  • W. Perry et al.

    A multimethod approach to assessing perseverations in schizophrenia patients

    Schizophr. Res.

    (1998)
  • B.J. Sahakian et al.

    Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people

    Lancet Psychiatry

    (2015)
  • J. van Enkhuizen et al.

    Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice

    Behav. Brain Res.

    (2014)
  • J.T. Willie et al.

    Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates

    Neuroscience

    (2005)
  • J.W. Young et al.

    Action of modafinil–increased motivation via the dopamine transporter inhibition and D1 receptors?

    Biol. Psychiatry

    (2010)
  • J.W. Young et al.

    The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration

    Pharmacol. Biochem. Behav.

    (2010)
  • J.W. Young et al.

    A reverse-translational approach to bipolar disorder: rodent and human studies in the behavioral pattern monitor

    Neurosci. Biobehav Rev.

    (2007)
  • J.W. Young et al.

    The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: separating response inhibition from premature responding

    Behav. Brain Res.

    (2011)
  • J.V. Baranski et al.

    Effects of modafinil on cognitive and meta-cognitive performance

    Hum. Psychopharmacol.

    (2004)
  • S.A. Barnes et al.

    D(1) receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test

    Psychopharmacol. Berl.

    (2012)
  • J.C. Bensadoun et al.

    Free operant and discrete trial performance of mice in the nine-hole box apparatus: validation using amphetamine and scopolamine

    Psychopharmacol. Berl.

    (2004)
  • C.W. Berridge

    Neural substrates of psychostimulant-induced arousal

    Neuropsychopharmacology

    (2006)
  • R.J. Chiarello et al.

    The use of psychostimulants in general psychiatry. A reconsideration

    Arch. Gen. Psychiatry

    (1987)
  • Z.A. Cope et al.

    Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges

    Psychopharmacol. Berl.

    (2016)
  • P. Fusar-Poli et al.

    Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials

    Schizophr. Bull.

    (2015)
  • J.O. Goldberg et al.

    Performance of psychiatric inpatients and intellectually deficient individuals on a task that assesses the validity of memory complaints

    J. Clin. Psychol.

    (1986)
  • Cited by (18)

    • The relationship between novelty-seeking traits and behavior: Establishing construct validity for the human Behavioral Pattern Monitor

      2022, Psychiatry Research
      Citation Excerpt :

      The 200 mg and 400 mg doses of modafinil were selected because 200 mg is a typical starting clinically therapeutic dose, and 400 mg has been shown to affect risk-taking behavior in healthy adults (Killgore et al., 2008). We have previously published that these doses had a beneficial effect on attention in this cohort of subjects (Cope et al., 2017). The University of California San Diego (UCSD) School of Medicine's institutional review board approved the study.

    • Noradrenergic Transmission at Alpha1-Adrenergic Receptors in the Ventral Periaqueductal Gray Modulates Arousal

      2019, Biological Psychiatry
      Citation Excerpt :

      This circuit could be a target for developing therapeutics to treat arousal disturbances and explain a mechanism for some currently available treatments. For example, modafinil (Provigil; Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel) promotes wakefulness without causing hyperactivity (81) via contributions from both NE and DA (12). Future studies should examine the source and functional contributions of glutamatergic neuronal inputs to the vPAG and which vPAGDA projections are critical for increasing arousal.

    • Amphetamine improves mouse and human attention in the 5-choice continuous performance test

      2018, Neuropharmacology
      Citation Excerpt :

      Critically, consistency of performance across humans and mice enable research with model organisms for molecular, cellular, and circuit level analyses, which can be used to delineate the neural substrates of attention and potential pathological processes (such as in ADHD or schizophrenia). In mice, 5C-CPT performance was impaired by scopolamine, a non-specific mAChR antagonist (Young et al., 2013), and improved in both mouse and human by D-amp (present data) and by modafinil in humans, a dopamine transporter (DAT) and norepinephrine transporter (NET) inhibitor (Cope et al., 2017). These data corroborate the importance of DAT/NET inhibition in improving attentional functioning.

    View all citing articles on Scopus
    View full text